China National Accord Medicines (000028) Fundamentals 2026 — P/E 10.5x, Revenue Analysis | SniperIQ
China National Accord Medicines (000028) is a CN-listed Healthcare company in Medical - Distribution with a market capitalization of ¥11.0B, trading at ¥20.61 on the SHZ. This SniperIQ fundamentals page covers China National Accord Medicines's valuation (P/E 10.5x, P/B 0.6x), profitability (net margin 1.5%), revenue (¥73.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China National Accord Medicines's market cap?
China National Accord Medicines (000028) has a market capitalization of approximately ¥11.0B, trading at ¥20.61 on the SHZ. Market cap moves with the live share price.
What is China National Accord Medicines's P/E ratio?
China National Accord Medicines's trailing twelve-month P/E ratio is 10.5x, with a price-to-book (P/B) of 0.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China National Accord Medicines?
China National Accord Medicines runs a net profit margin of 1.5%, a gross margin of 9.8%, and an operating margin of 2.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China National Accord Medicines generate?
China National Accord Medicines reported revenue of ¥73.3B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 2.04. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China National Accord Medicines pay a dividend?
China National Accord Medicines offers a trailing dividend yield of about 3.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China National Accord Medicines financially healthy?
China National Accord Medicines carries a debt-to-equity ratio of 0.69x and a current ratio of 1.56x, with a market beta of 0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China National Accord Medicines a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China National Accord Medicines (000028) the key facts are: market cap ¥11.0B, P/E 10.5x, revenue ¥73.3B, 52-week range 18.7-24.93636. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China National Accord Medicines's full fundamentals live
Get China National Accord Medicines's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.